



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant: Wilfried Lubisch, et al.) Group Art Unit: 1624
Serial No.: 10/041,556) Examiner: Brenda Libby Coleman
Filing Date: January 10, 2002)
For: Dibenzodiazepine Derivatives,)
Their Preparation and Use)

INFORMATION DISCLOSURE STATEMENT

Commissioner for Patents
P. O. Box 1450
Alexandria, Virginia 22313-1450

Sir:

Attached Form PTO/1449A lists references which may be considered to be material to the above-identified application by the Patent Examiner. Copies of the references are enclosed.

Entry into the record is respectfully requested.

If any additional fee might be required in connection with this matter, please charge our Deposit Account No. 23-0785.

Respectfully submitted,

WOOD, PHILLIPS, KATZ, CLARK & MORTIMER


By Martin L. Katz
Martin L. Katz, Reg. No. 25,011

May 4, 2004


Citicorp Center, Suite 3800
500 West Madison Street
Chicago, IL 60661-2511
(312) 876-1800

37 CFR 1.8
CERTIFICATE OF MAILING

I hereby certify that this correspondence is being deposited with the United States Postal Service, as First Class Mail in an envelope addressed to: Commissioner for Patents, Alexandria, Virginia 22313-1450 on May 4, 2004.



Rebecca J. Willis



Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.


INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use as many sheets as necessary)				Application Number	10/041,556
				Filing Date	January 10, 2002
				First Named Inventor	Wilfried Lubisch
				Group Art Unit	1624
				Examiner Name	
Sheet	1	of	4	Attorney Docket No.	ABB10010P0690US

U.S. PATENT DOCUMENTS					
Examiner Initials*	Cite No. ¹	U.S. Patent Document	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines Where Relevant Passages or Relevant Figures Appear
		Number Kind Code ² (if known)			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			

FOREIGN PATENT DOCUMENTS						
Examiner Initials'	Cite No. ¹	Foreign Patent Document	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T ⁶
		Country Code ³ -Number ⁴ -Kind Code ⁵ (if known)				
		WO 01/16136 A2	March 8, 2001	Agouron Pharmaceuticals, Inc. Cancer Research Campaign Technology Limited		
		WO 01/23390 A2	April 5, 2001	BASF Aktiengesellschaft		
Examiner Signature				Date Considered		

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ¹ Applicant's unique citation designation number (optional). ² See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standards ST.16, if possible. ⁶ Applicant is to place a checkmark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) and application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: **Commissioner For Patents, P.O. Box 1450, Alexandria, VA 22313-1450.**



Substitute for form 1449A/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(Use as many sheets as necessary)</i>				Application Number	10/041,556
				Filing Date	January 10, 2002
				First Named Inventor	Wilfried Lubisch
				Group Art Unit	1624
				Examiner Name	
Sheet	3	of	4	Attorney Docket No.	ABB10010P0690US

OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No.	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
		BURKART, et al., Mice lacking the poly (ADP-ribose) polymerase gene are resistant to pancreatic beta-cell destruction and diabetes development induced by streptozocin; March 1999, pp. 314-319; Vol. 5, No. 3, Nature Medicine	
		CHEN, et al., Potentiation of the antitumor activity of cisplatin in mice by 3-aminobenzamide and nicotinamide; (1998), pp. 303-307; Vol. 22, Cancer Chemotherapy and Pharmacology.	
		EHRlich, et al., Inhibition of the induction of collagenase by interleukin 18 in cultured rabbit synovial fibroblasts after treatment with the poly(ADP-ribose)-polymerase inhibitor 3-aminobenzamide; March 1995, pp. 171-172; Vol. 15; Rheumatol Int.	
		GÄKEN, et al., Efficient Retroviral Infection of Mammalian Cells Is Blocked by Inhibition of Poly (ADP-Ribose) Polymerase Activity; June 1996; pp. 3992-4000; Vol. 70, No. 6; Journal of Virology	
		CUZZOCREA, et al., Beneficial effects of 3-aminobenzamide, an inhibitor of poly (ADP-ribose) synthetase in a rat model of splanchnic artery occlusion and reperfusion; 1997; pp. 1065-1074; Vol. 121; British Journal of Pharmacology	
		CUZZOCREA, et al., Protective effects of 3-aminobenzamide, an inhibitor of poly (ADP-ribose) synthase in a carrageenan-induced model of local inflammation; 1998, pp. 67-76; Vol. 342; European Journal of Pharmacology	
		IKAI, et al., Immunohistochemical Demonstration of Poly (Adenosine Diphosphate-Ribose) Synthetase in Bovine Tissues; 1983; pp. 1261-1264; Vol. 31, No. 11; The Journal of Histochemistry and Cytochemistry	
		KRÖGER, et al., Synergistic Effects of Thalidomide and Poly(ADP-Ribose) Polymerase Inhibition on Type II Collagen-Induced Arthritis in Mice; 1996; pp. 203-215; Vol. 20, No. 2; Inflammation	
		SHALL, SYDNEY; ADP-Ribose in DNA Repair; A New Component of DNA Excision Repair; 1984; pp. 1-65; Vol. II, Advances in Radiation Biology	
		KAMEOKA, et al., Poly (ADP-ribose) Polymerase Is Involved in PMA-induced Activation of HIV-1 in U1 Cells by Modulating the LTR Function; 1999; pp. 285-289; Vol. 262; Biochemical and Biophysical Research Communications	
		SATOH, et al., Role of poly(ADP-ribose) formation of DNA repair; March 1992; pp. 356-358; Vol. 356; Nature	
		SZABÓ, et al., Protection against peroxynitrite-induced fibroblast injury and arthritis development by inhibition of poly(ADP-ribose) synthase; March 1998; 3867-3872; Vol. 95; Proc. Natl. Acad. Sci. USA	
		WELTIN, et al., Immunosuppressive Activities of 6(5H)-Phenanthridinone, A New Poly (ADP-Ribose) Polymerase Inhibitor; 1995; pp. 265-271, Vol. 17, No. 4; Int. J. Immunopharmac	

		THIEMERMANN, et al., Inhibition of the activity of poly (ADP ribose) synthetase reduces ischemia -reperfusion injury in the heart and skeletal muscle; January 1997; pp. 679-683; Vol. 94; Proc. Natl. Acad. Sci. USA		
Examiner Signature			Date Considered	

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹Applicant's unique citation designation number (optional). ²Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) and application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner For Patents, P.O. Box 1450, Alexandria, VA 22313-1450.